RxDoctor Payments Data

Nicholas Birlew, DO

Family Medicine · Stockton, CANPI 1821188483

Payments from drug & device makers

$8,952in general payments, 2019–2025

Across 499 payments — averaging $17.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$1K
  • AbbVie$863
  • Novo Nordisk$777
  • AstraZeneca$774
  • Pfizer$762
  • Lilly USA, LLC$716
  • plus $4K from 37 others

What the payments were for

  • Food & beverage$8,938100%
  • Education$150%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,952 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$1,957
Medicare patients
18
Services billed
48

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin50$52,921
OzempicSemaglutide46$47,165
RybelsusSemaglutide12$23,194
JanuviaSitagliptin Phosphate15$21,734
EliquisApixaban20$20,316
XareltoRivaroxaban17$16,517
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$13,100
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen240$6,015
PremarinEstrogens, Conjugated15$4,060
Losartan Potassium318$4,045
Levothyroxine Sodium163$2,884
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$2,824
Atorvastatin Calcium158$2,539
Wixela InhubFluticasone Propion/Salmeterol15$2,053
Omeprazole145$2,008

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$777$70,35958 claims
Boehringer IngelheimJardiance$1,317$52,92150 claims
PfizerEliquis, Premarin$762$24,37635 claims
MerckJanuvia$185$21,73415 claims
Johnson & JohnsonXarelto$358$16,51717 claims
GSKTrelegy Ellipta$212$13,10022 claims
Almatica Pharma LLCSertraline Hcl$122$48244 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.

Other family medicine in Stockton

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →